New drug targets tumors in early trial
NCT ID NCT04261413
First seen Apr 01, 2026 · Last updated May 24, 2026 · Updated 9 times
Summary
This early-phase study tested a new drug called RS-0139 in 16 people with advanced solid tumors that had come back or spread. The goal was to find the safest dose and see how the drug works in the body. The drug is designed to target tumors directly, and researchers monitored side effects and tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi
Ankara, Turkey (Türkiye)
-
Koç University Hospital Phase I Center
Istanbul, Turkey (Türkiye)
Conditions
Explore the condition pages connected to this study.